Compare GKOS & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | KRYS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.2B |
| IPO Year | 2015 | 2017 |
| Metric | GKOS | KRYS |
|---|---|---|
| Price | $238.12 | $315.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $243.85 | ★ $388.22 |
| AVG Volume (30 Days) | ★ 1.5M | 263.7K |
| Earning Date | 10-28-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | N/A | ★ 5.66 |
| Revenue | ★ $507,442,000.00 | $389,130,000.00 |
| Revenue This Year | $53.82 | $27.84 |
| Revenue Next Year | $28.56 | $27.62 |
| P/E Ratio | ★ N/A | $53.69 |
| Revenue Growth | 32.33 | ★ 33.94 |
| 52 Week Low | $93.78 | $203.35 |
| 52 Week High | $255.19 | $382.54 |
| Indicator | GKOS | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 59.90 | 50.32 |
| Support Level | $147.72 | $287.37 |
| Resistance Level | $255.19 | $317.53 |
| Average True Range (ATR) | 11.84 | 12.10 |
| MACD | -1.49 | 1.41 |
| Stochastic Oscillator | 43.31 | 79.76 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.